Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Jazz Pharmaceuticals (JAZZ) Stock Price & Analysis
1,291 Followers
JAZZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$103.01 - $146.70
Previous Close$111.21
Volume771.17K
Average Volume (3M)644.62K
Market Cap
$7.01B
Enterprise Value$11.45B
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$5.78B
Price to Earnings (P/E)24.2
Beta0.53
Next Earnings
Aug 06, 2024EPS Estimate
$4.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.60
Shares Outstanding63,039,618
10 Day Avg. Volume667,164
30 Day Avg. Volume644,617
Standard Deviation0.09
R-Squared0.15
Alpha-0.00537
Financial Highlights & Ratios
Price to Book (P/B)-2.02
Price to Sales (P/S)1.92
Price to Cash Flow (P/CF)10.40
P/FCF Ratio8.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit2.73
Enterprise Value/Ebitda19.53
Forecast
1Y Price Target
$189.15Price Target Upside70.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Jazz Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceThe company did reiterate 2024 financial guidance, including for total revenue of $4.0-$4.2B.
Pipeline DevelopmentMultiple pipeline readouts remain on track for this year.
Product PerformanceXywav, Jazz’s biggest product and cash-flow driver, exceeded expectations on patient adds.
Bears Say
Drug SalesEpidiolex sales were negatively impacted by inventory drawdown.
Earnings GuidanceJazz reported a lower than expected non-GAAP EPS of $5.02 compared to the consensus of $5.18, which could raise concerns about profitability going forward.
Financial Performance1Q24 revenue of $902M was lower than consensus of $954M.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $103.01 and its highest was $146.70 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 89 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 01, 2024. The company reported $2.68 earnings per share for the quarter, missing the consensus estimate of $4.179 by -$1.499.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is $4.74.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 63,039,620 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $2.68 in its last earnings report, missing expectations of $4.179. Following the earnings report the stock price went down -0.925%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 156M.
---
Jazz Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$189.15 (70.87% Upside)
$189.15 (70.87% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 153.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $449.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.22%
12-Months-Change
Fundamentals
Return on Equity
9.41%
Trailing 12-Months
Asset Growth
2.53%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q1 2024
0:00 / 0:00
---
JAZZ Stock 12 Month Forecast
Average Price Target
$189.15
▲(70.87% Upside)
Technical Analysis
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+3.18%
reiterated a buy rating 8 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +3.18% per trade.
---